CPI Card Group (PMTS) Margin Compression Challenges Bullish Narratives Ahead Of Q1 2026

Advertisement

Q1 2026 earnings snapshot for CPI Card Group (PMTS)

CPI Card Group (PMTS) has opened Q1 2026 earnings season with investors focused on how its recent revenue base of about US$543.5 million and trailing EPS of roughly US$1.32 over the last reported twelve months frame the story after a period of softer profitability. Over the past year, the company has seen revenue progress from US$480.6 million in 2024 Q4 to US$543.5 million in 2025 Q4, while quarterly EPS has moved between US$0.05 and US$0.64, setting up a results narrative that turns on how far margins can stabilise from compressed levels.

See our full analysis for CPI Card Group.

With the headline numbers in place, the next step is to see how this earnings profile lines up against the widely followed bullish and cautious narratives that have built around the stock.

See what the community is saying about CPI Card Group

NasdaqGM:PMTS Earnings & Revenue History as at May 2026
NasdaqGM:PMTS Earnings & Revenue History as at May 2026

Margins compressed as profit falls to 2.8%

  • Net profit margin has moved from 4.1% to 2.8% over the last year, even though trailing twelve month revenue sits around US$543.5 million and net income is about US$15.0 million.
  • Consensus narrative expects higher margin products and automation to help over time, yet the current 2.8% margin contrasts with that view:
    • The story highlights higher margin metal, eco-friendly and digital solutions, but recent margins sit below the prior 4.1% level that investors had seen a year ago.
    • Investments like the new Indiana facility are aimed at efficiency, while trailing earnings have been declining at about 6.6% per year, so the expected benefits have not yet shown up in the reported margin.

Negative equity and weak interest cover raise balance sheet questions

  • Shareholders' equity is negative and interest payments are not well covered by earnings, which together point to material financial strain despite trailing net income of about US$15.0 million.
  • Bears focus on leverage and cash flow pressure, and the numbers give that concern a clear anchor:
    • Net leverage was recently cited at 3.6x, up from 3.1x, while earnings have been shrinking at about 6.6% per year over five years, so there is less profit supporting higher debt.
    • With margins compressed to 2.8% and equity in a deficit, critics argue that any further pressure on earnings could make refinancing or higher interest costs more painful.
On these figures, skeptics argue the real story is balance sheet resilience rather than just the next quarter’s revenue print, and they watch how CPI Card Group handles debt and cash generation in this phase. 🐻 CPI Card Group Bear Case

Valuation gap: US$15.99 price vs US$52.96 DCF fair value

  • The stock trades at US$15.99 with a P/E of 12.3x, slightly above peers at 12.1x, while a stated DCF fair value of about US$52.96 and a reference analyst target of US$27.50 together point to a wide spread between models and the current share price.
  • Bullish investors lean on that gap, but the earnings track record keeps the debate alive:
    • Trailing earnings of roughly US$14.9 million and a 6.6% annual earnings decline over five years are used by critics to question how quickly any valuation gap could close.
    • Supporters point out that the share price sits well below both the DCF fair value of US$52.96 and the US$27.50 analyst target reference, arguing the market is already accounting for the weaker margins and leverage.
For anyone weighing that valuation spread against the recent margin and balance sheet pressure, it helps to see how bullish investors connect the dots between today’s compressed profitability and their longer term thesis. 🐂 CPI Card Group Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CPI Card Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both concerns and optimism in the mix, the real question is how you see the balance between them. Take a moment to test the figures and sentiment against your own expectations, and then check the 2 key rewards and 5 important warning signs.

See What Else Is Out There

CPI Card Group's compressed 2.8% profit margin, negative equity and weak interest cover show that balance sheet resilience and financial risk are key concerns for investors.

If you want stocks where debt and cash flow look more robust, take a few minutes today to compare CPI Card Group against 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:PMTS

CPI Card Group

Provides physical and digital payment solutions for financial institutions, processors, fintechs, prepaid program managers, and other organizations in the United States.

Very undervalued with moderate growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0